The latest price target for RxSight (NASDAQ:RXST) was reported by Stifel on December 20, 2024. The analyst firm set a price target for $40.00 expecting RXST to rise to within 12 months (a possible 18.69% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for RxSight (NASDAQ:RXST) was provided by Stifel, and RxSight downgraded their hold rating.

The last upgrade for RxSight Inc happened on December 13, 2023 when Wells Fargo raised their price target to $42. Wells Fargo previously had an equal-weight for RxSight Inc.

The last downgrade for RxSight Inc happened on December 20, 2024 when Stifel changed their price target from $65 to $40 for RxSight Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RxSight, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RxSight was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest RxSight (RXST) rating was a downgraded with a price target of $65.00 to $40.00. The current price RxSight (RXST) is trading at is $33.70, which is out of the analyst’s predicted range.